WallStreetZenWallStreetZen

NASDAQ: JAZZ
Jazz Pharmaceuticals PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for JAZZ

Based on 18 analysts offering 12 month price targets for Jazz Pharmaceuticals PLC

Min Forecast
$229.00-5.97%
Avg Forecast
$299.44+22.95%
Max Forecast
$337.00+38.37%

Should I buy or sell JAZZ stock?

Based on 18 analysts offering ratings for Jazz Pharmaceuticals PLC.

Strong Buy
Strong Buy
14 analysts 77.78%
Buy
3 analysts 16.67%
Hold
1 analysts 5.56%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although JAZZ's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates JAZZ as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their JAZZ stock forecasts and price targets.

JAZZ stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-11-03
lockedlocked$00.00+00.00%2026-11-03Find Out Why
lockedlocked$00.00+00.00%2026-11-03
lockedlocked$00.00+00.00%2026-11-03Find Out Why
lockedlocked$00.00+00.00%2026-10-07Find Out Why
Citigroup
Top 6%
95
Strong BuyInitiates Coverage On$325.00+33.45%2026-09-30Find out why
Goldman Sachs
Top 24%
77
Strong BuyReinstates$337.00+38.37%2026-09-24Find out why
UBS
Top 12%
89
Strong BuyMaintains$337.00+38.37%2026-09-11Find out why
Deutsche Bank
Top 10%
91
Strong BuyMaintains$300.00+23.18%2026-08-26Find out why
Needham
Top 1%
100
BuyMaintains$310.00+27.29%2026-08-26Find out why

1 of 2

Forecast return on equity

Is JAZZ forecast to generate an efficient return?

Company
48.77%
Industry
17.28%
Market
159.92%
JAZZ's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is JAZZ forecast to generate an efficient return on assets?

Company
17.04%
Industry
19.48%
JAZZ is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

JAZZ earnings per share forecast

What is JAZZ's earnings per share in the next 3 years based on estimates from 25 analysts?

Avg 1 year Forecast
$15.28+319.76%
Avg 2 year Forecast
$27.11+644.8%
Avg 3 year Forecast
$29.38+707.25%
JAZZ's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

JAZZ revenue forecast

What is JAZZ's revenue in the next 3 years based on estimates from 25 analysts?

Avg 1 year Forecast
$4.9B+3.92%
Avg 2 year Forecast
$5.1B+8.35%
Avg 3 year Forecast
$5.5B+17.5%
JAZZ's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

JAZZ earnings growth forecast

How is JAZZ forecast to perform vs Biotechnology companies and vs the US market?

Company
104.41%
Industry
10.95%
Market
32.32%
JAZZ's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
JAZZ's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
JAZZ's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

JAZZ revenue growth forecast

How is JAZZ forecast to perform vs Biotechnology companies and vs the US market?

Company
5.27%
Industry
34.79%
Market
12.37%
JAZZ's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
JAZZ's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

JAZZ vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
JAZZ$243.55$299.44+22.95%Strong Buy
BBIO$77.93$108.39+39.08%Strong Buy
SMMT$17.84$26.99+51.27%Buy
ASND$259.85$313.13+20.50%Strong Buy
EXEL$71.74$59.58-16.95%Hold
View Top Biotech Stocks

Jazz Pharmaceuticals Stock Forecast FAQ

Is Jazz Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 18 Wall Street analysts covering (NASDAQ: JAZZ) stock is to Strong Buy JAZZ stock.

Out of 18 analysts, 14 (77.78%) are recommending JAZZ as a Strong Buy, 3 (16.67%) are recommending JAZZ as a Buy, 1 (5.56%) are recommending JAZZ as a Hold, 0 (0%) are recommending JAZZ as a Sell, and 0 (0%) are recommending JAZZ as a Strong Sell.

If you're new to stock investing, here's how to buy Jazz Pharmaceuticals stock.

What is JAZZ's earnings growth forecast for 2026-2028?

(NASDAQ: JAZZ) Jazz Pharmaceuticals's forecast annual earnings growth rate of 104.41% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.95%, and it is also forecast to beat the US market's average forecast earnings growth rate of 32.32%.

Jazz Pharmaceuticals's earnings in 2026 is $205,951,000.On average, 25 Wall Street analysts forecast JAZZ's earnings for 2026 to be $980,763,782, with the lowest JAZZ earnings forecast at $879,415,688, and the highest JAZZ earnings forecast at $1,076,354,118. On average, 25 Wall Street analysts forecast JAZZ's earnings for 2027 to be $1,740,222,970, with the lowest JAZZ earnings forecast at $1,450,595,548, and the highest JAZZ earnings forecast at $2,166,187,938.

In 2028, JAZZ is forecast to generate $1,886,124,685 in earnings, with the lowest earnings forecast at $1,454,998,917 and the highest earnings forecast at $2,135,184,626.

What is JAZZ's revenue growth forecast for 2026-2028?

(NASDAQ: JAZZ) Jazz Pharmaceuticals's forecast annual revenue growth rate of 5.27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.37%.

Jazz Pharmaceuticals's revenue in 2026 is $4,718,126,000.On average, 25 Wall Street analysts forecast JAZZ's revenue for 2026 to be $314,718,921,956, with the lowest JAZZ revenue forecast at $298,800,037,060, and the highest JAZZ revenue forecast at $326,914,841,836. On average, 25 Wall Street analysts forecast JAZZ's revenue for 2027 to be $328,134,433,824, with the lowest JAZZ revenue forecast at $297,002,743,604, and the highest JAZZ revenue forecast at $356,185,049,548.

In 2028, JAZZ is forecast to generate $355,864,104,288 in revenue, with the lowest revenue forecast at $312,408,116,084 and the highest revenue forecast at $393,093,754,448.

What is JAZZ's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: JAZZ) forecast ROA is 17.04%, which is lower than the forecast US Biotechnology industry average of 19.48%.

What is JAZZ's Price Target?

According to 18 Wall Street analysts that have issued a 1 year JAZZ price target, the average JAZZ price target is $299.44, with the highest JAZZ stock price forecast at $337.00 and the lowest JAZZ stock price forecast at $229.00.

On average, Wall Street analysts predict that Jazz Pharmaceuticals's share price could reach $299.44 by Nov 3, 2027. The average Jazz Pharmaceuticals stock price prediction forecasts a potential upside of 22.95% from the current JAZZ share price of $243.55.

What is JAZZ's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: JAZZ) Jazz Pharmaceuticals's current Earnings Per Share (EPS) is $3.64. On average, analysts forecast that JAZZ's EPS will be $15.28 for 2026, with the lowest EPS forecast at $13.70, and the highest EPS forecast at $16.77. On average, analysts forecast that JAZZ's EPS will be $27.11 for 2027, with the lowest EPS forecast at $22.60, and the highest EPS forecast at $33.75. In 2028, JAZZ's EPS is forecast to hit $29.38 (min: $22.67, max: $33.26).

What is JAZZ's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: JAZZ) forecast ROE is 48.77%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.